Plain-English translation of NCT06916637 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This trial is testing a new imaging technology called 18F-HER2 Affibody PET scanning, which is designed to help doctors detect and monitor HER2-positive breast cancer more accurately than traditional methods. Instead of using invasive biopsies, this scan works by injecting a small amount of radioactive tracer that specifically targets HER2 proteins in cancer cells, then taking pictures to see where the cancer is and how it's responding to treatment.
Current methods for diagnosing and monitoring HER2 breast cancer often require painful biopsies and don't show how HER2 expression changes over time during treatment. This new imaging approach could provide doctors with a non-invasive, more detailed picture of your cancer and help them personalize your treatment plan.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the new imaging tracer and then undergo a PET scan to create detailed pictures of your cancer. The study will track how well this imaging method works at detecting HER2 in your breast cancer and how it can help guide your treatment. You'll need to commit to using effective contraception during the study and for 6 months after your scan.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China